NEW YORK (GenomeWeb News) – Veracyte said after the close of the market on Tuesday that revenues for its fourth quarter rose 51 percent year over year.

The South San Francisco, Calif.-based firm recorded $6.8 million in revenues for the three months ended Dec. 31, 2013, up from $4.5 million in the year-ago fourth quarter. In a statement, Veracyte President and CEO Bonnie Anderson said, "We saw increases in fine needle aspiration sample volumes and cash collections during the fourth quarter, which is traditionally our strongest quarter."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.